Titre : Récepteurs CCR5

Récepteurs CCR5 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Case-Control Studies
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Récepteurs CCR5 : Questions médicales les plus fréquentes", "headline": "Récepteurs CCR5 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Récepteurs CCR5 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-05", "dateModified": "2025-03-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Récepteurs CCR5" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Récepteur VIH", "url": "https://questionsmedicales.fr/mesh/D015728", "about": { "@type": "MedicalCondition", "name": "Récepteur VIH", "code": { "@type": "MedicalCode", "code": "D015728", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.750.830.700" } } }, "about": { "@type": "MedicalCondition", "name": "Récepteurs CCR5", "alternateName": "Receptors, CCR5", "code": { "@type": "MedicalCode", "code": "D019713", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard G Pestell", "url": "https://questionsmedicales.fr/author/Richard%20G%20Pestell", "affiliation": { "@type": "Organization", "name": "Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, United States; Wistar Institute, Philadelphia, PA, United States; Xavier University School of Medicine, Woodbury, NY, United States. Electronic address: richard.pestell@bblumberg.org." } }, { "@type": "Person", "name": "Xuanmao Jiao", "url": "https://questionsmedicales.fr/author/Xuanmao%20Jiao", "affiliation": { "@type": "Organization", "name": "Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, United States." } }, { "@type": "Person", "name": "Yang Shen", "url": "https://questionsmedicales.fr/author/Yang%20Shen", "affiliation": { "@type": "Organization", "name": "Neurobiology, Psychiatry and Psychology Departments & Integrative Center for Learning and Memory, UCLA, Los Angeles, CA." } }, { "@type": "Person", "name": "Miou Zhou", "url": "https://questionsmedicales.fr/author/Miou%20Zhou", "affiliation": { "@type": "Organization", "name": "College of Dental Medicine, Western University of Health Sciences, Pomona, CA. Electronic address: mzhou@westernu.edu." } }, { "@type": "Person", "name": "Raquel Blanco", "url": "https://questionsmedicales.fr/author/Raquel%20Blanco", "affiliation": { "@type": "Organization", "name": "Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB/CSIC), Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Surgery for Recurrent Glioblastoma Multiforme: A Retrospective Case Control Study.", "datePublished": "2022-07-21", "url": "https://questionsmedicales.fr/article/35870781", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.wneu.2022.07.070" } }, { "@type": "ScholarlyArticle", "name": "Predictive Factors for Aortic Graft Infection: A Case-Control Study.", "datePublished": "2022-06-27", "url": "https://questionsmedicales.fr/article/35772668", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.avsg.2022.05.015" } }, { "@type": "ScholarlyArticle", "name": "Contributing factors of birth asphyxia in Thailand: a case-control study.", "datePublished": "2023-08-15", "url": "https://questionsmedicales.fr/article/37582743", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-023-05885-y" } }, { "@type": "ScholarlyArticle", "name": "Effect of Familial Longevity on Frailty and Sarcopenia: A Case-Control Study.", "datePublished": "2023-01-14", "url": "https://questionsmedicales.fr/article/36674289", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph20021534" } }, { "@type": "ScholarlyArticle", "name": "Attention and working memory in patients with prolactinomas: a case-control study.", "datePublished": "2022-12-29", "url": "https://questionsmedicales.fr/article/36581642", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-26331-7" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Récepteurs de surface cellulaire", "item": "https://questionsmedicales.fr/mesh/D011956" }, { "@type": "ListItem", "position": 6, "name": "Récepteurs viraux", "item": "https://questionsmedicales.fr/mesh/D011991" }, { "@type": "ListItem", "position": 7, "name": "Récepteur VIH", "item": "https://questionsmedicales.fr/mesh/D015728" }, { "@type": "ListItem", "position": 8, "name": "Récepteurs CCR5", "item": "https://questionsmedicales.fr/mesh/D019713" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Récepteurs CCR5 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Récepteurs CCR5", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Récepteurs CCR5", "description": "Comment diagnostiquer une infection par le VIH ?\nQuels tests évaluent les récepteurs CCR5 ?\nQuels symptômes indiquent une infection par le VIH ?\nComment évaluer la résistance au VIH ?\nQuel rôle joue CCR5 dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Récepteurs CCR5", "description": "Quels sont les symptômes d'une infection par le VIH ?\nComment les récepteurs CCR5 affectent-ils l'immunité ?\nQuels symptômes sont liés à l'inhibition de CCR5 ?\nLes symptômes varient-ils selon le génotype de CCR5 ?\nQuels signes indiquent une progression de l'infection ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Récepteurs CCR5", "description": "Comment prévenir l'infection par le VIH ?\nQuel rôle joue l'éducation dans la prévention ?\nLes vaccins contre le VIH existent-ils ?\nComment la PrEP aide-t-elle à prévenir le VIH ?\nLes tests réguliers sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Récepteurs CCR5", "description": "Quels traitements ciblent les récepteurs CCR5 ?\nComment les traitements antirétroviraux agissent-ils ?\nQuels sont les effets secondaires des inhibiteurs de CCR5 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nComment surveiller l'efficacité du traitement ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Récepteurs CCR5", "description": "Quelles complications peuvent survenir avec le VIH ?\nComment les récepteurs CCR5 influencent-ils les complications ?\nQuels sont les risques de résistance aux traitements ?\nLes complications sont-elles réversibles ?\nComment prévenir les complications liées au VIH ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Récepteurs CCR5", "description": "Quels sont les principaux facteurs de risque du VIH ?\nLe génotype de CCR5 influence-t-il le risque d'infection ?\nComment l'usage de drogues affecte-t-il le risque ?\nLes antécédents familiaux influencent-ils le risque ?\nQuel rôle joue l'âge dans le risque d'infection ?", "url": "https://questionsmedicales.fr/mesh/D019713?mesh_terms=Case-Control+Studies&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par le VIH ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un test sanguin détectant les anticorps ou l'ARN du VIH est utilisé." } }, { "@type": "Question", "name": "Quels tests évaluent les récepteurs CCR5 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de surface cellulaire peuvent être effectués." } }, { "@type": "Question", "name": "Quels symptômes indiquent une infection par le VIH ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Symptômes incluent fièvre, fatigue, éruptions cutanées et ganglions enflés." } }, { "@type": "Question", "name": "Comment évaluer la résistance au VIH ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de résistance virale mesurent l'efficacité des traitements antirétroviraux." } }, { "@type": "Question", "name": "Quel rôle joue CCR5 dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "CCR5 est un co-récepteur essentiel pour l'entrée du VIH dans les cellules." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection par le VIH ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, fatigue, maux de tête et éruptions cutanées." } }, { "@type": "Question", "name": "Comment les récepteurs CCR5 affectent-ils l'immunité ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils modulent la réponse immunitaire, influençant l'inflammation et l'infection." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'inhibition de CCR5 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Une inhibition peut réduire l'inflammation, mais causer des effets secondaires." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le génotype de CCR5 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variations génétiques peuvent influencer la gravité des symptômes." } }, { "@type": "Question", "name": "Quels signes indiquent une progression de l'infection ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Perte de poids, infections opportunistes et fatigue chronique sont des signes." } }, { "@type": "Question", "name": "Comment prévenir l'infection par le VIH ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des préservatifs, se faire dépister et prendre des médicaments préventifs." } }, { "@type": "Question", "name": "Quel rôle joue l'éducation dans la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sur le VIH et les comportements à risque est cruciale pour la prévention." } }, { "@type": "Question", "name": "Les vaccins contre le VIH existent-ils ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, aucun vaccin efficace n'est disponible, mais des recherches sont en cours." } }, { "@type": "Question", "name": "Comment la PrEP aide-t-elle à prévenir le VIH ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "La PrEP réduit le risque d'infection en bloquant l'entrée du VIH dans les cellules." } }, { "@type": "Question", "name": "Les tests réguliers sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage régulier aide à détecter l'infection précocement et à prévenir sa propagation." } }, { "@type": "Question", "name": "Quels traitements ciblent les récepteurs CCR5 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les inhibiteurs de CCR5, comme le maraviroc, sont utilisés dans le VIH." } }, { "@type": "Question", "name": "Comment les traitements antirétroviraux agissent-ils ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils bloquent la réplication virale, empêchant le VIH d'infecter de nouvelles cellules." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des inhibiteurs de CCR5 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent causer des nausées, des éruptions cutanées et des infections respiratoires." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Non, l'efficacité dépend du génotype du VIH et de la réponse individuelle." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des tests réguliers de charge virale et de CD4 sont nécessaires pour évaluer la réponse." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le VIH ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent les infections opportunistes et les cancers associés au VIH." } }, { "@type": "Question", "name": "Comment les récepteurs CCR5 influencent-ils les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent moduler la réponse immunitaire, augmentant le risque de complications." } }, { "@type": "Question", "name": "Quels sont les risques de résistance aux traitements ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise adhésion au traitement peut entraîner une résistance virale et des complications." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment prévenir les complications liées au VIH ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement antirétroviral efficace et un suivi médical régulier sont essentiels." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque du VIH ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les rapports sexuels non protégés, le partage de seringues et l'absence de dépistage." } }, { "@type": "Question", "name": "Le génotype de CCR5 influence-t-il le risque d'infection ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines variations génétiques peuvent conférer une protection contre le VIH." } }, { "@type": "Question", "name": "Comment l'usage de drogues affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage de drogues injectables augmente le risque de transmission du VIH par le partage de seringues." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies immunitaires peuvent augmenter le risque." } }, { "@type": "Question", "name": "Quel rôle joue l'âge dans le risque d'infection ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les jeunes adultes sont souvent plus à risque en raison de comportements à risque plus fréquents." } } ] } ] }

Sources (10000 au total)

Surgery for Recurrent Glioblastoma Multiforme: A Retrospective Case Control Study.

The role of surgery in recurrent glioblastoma multiforme (GBM) remains a controversial topic. The goal of this study was to perform a case control analysis including time to tumor recurrence as an add... Our brain tumor database was reviewed over a 10-year period for all adult (≥18 years old) patients with primary isocitrate dehydrogenase wildtype GBM who received surgery for recurrent disease. These ... A total of 174 adult patients with GBM were included in the study, 87 patients who received surgery for recurrent GBM (surgery cohort) and 87 patients who did not receive surgery for recurrent GBM (no... Surgery for recurrent GBM leads to improved survival independent of age, Karnofsky Performance Scale, and time to tumor recurrence. Patients with time to tumor recurrence >6 months benefit most from a...

Predictive Factors for Aortic Graft Infection: A Case-Control Study.

Graft infections are one of the most serious complications in vascular surgery, with high mortality rates. Few studies addressed risk factors associated with a higher susceptibility to infection. The ... We designed a retrospective, case-control study from patients subjected to open aortic repair between 2013 and 2019. Cases of AGI were defined according to the management of aortic graft infection col... Most graft infections occurred in a late period (n = 17; 85%), after a median interval of 13.5 months interquartile range (IQR 1.5-36). Gram-negative bacteria were most frequently isolated in infected... The risk of AGI seems to be higher in patients with concurrent malignancy, alcohol abuse or prolonged hospital stays. Strategies to mitigate this complication in these patients are of utmost importanc...

Contributing factors of birth asphyxia in Thailand: a case-control study.

Birth asphyxia is of significant concern because it impacts newborn health from low to severe levels. In Thailand, birth asphyxia remains a leading cause of delayed developmental health in children un... A case-control design was conducted on a sample of 4256 intrapartum chart records. The samples were selected based on their Apgar scores in the first minute of life. A low Apgar score (≤ 7) was chosen... The odds of birth asphyxia increases in the university and advanced hospitals but the university hospitals had the highest quality of care. The advanced and secondary hospitals had average nurse work-... Birth asphyxia problems may be resolved in the health service management offered by reducing the nurse work-hours. Excellent quality of care required the primary nursing care model combined with a tea...

Treatment of vulvar cancer recurrence with electrochemotherapy: a case-control study.

Electrochemotherapy (ECT) is a combined treatment method based on electroporation and simultaneous chemotherapy. In cases where radiotherapy has previously been used, surgery is often the only treatme... Eleven patients with single vulvar cancer recurrence were treated with ECT and followed up for 12 months. As a control group, 15 patients with single vulvar cancer recurrence were treated with wide lo... The probability curves for local tumor control did not differ between the ECT group and the surgical group (p = 0.694). The mean hospital stay and the mean duration of procedure were statistically sig... In this case-control study, treatment of vulvar cancer recurrence with ECT for non-palliative purposes was comparable to surgical treatment in terms of effectiveness. The results need to be confirmed ...

Influence of systemic sclerosis on periodontal health: A case-control study.

Patients with systemic sclerosis (SSc) present various clinical and radiological oral manifestations. However, precise evaluation of the oral features associated with diffuse cutaneous SSc (dcSSc) and... SSc patients and matched controls underwent standardized oral examination and cone-beam computed tomography (CBCT). Levels of interleukin-6 (IL-6), chemokine (C-X-C motif) ligand 4 (CXCL-4) and matrix... Thirty-nine SSc patients and 39 controls were included. SSc patients exhibited increased PDL surface, higher number of missing teeth as well as elevated IL-6, MMP-9 and CXCL-4 levels. Reduced mouth op... SSc is associated with PDL space widening, impaired oral health and OHRQoL....